37000 GRAND RIVER AVE., FARMINGTON HILLS, MI
Investor Presentation
Appoints Rob Gagnon as Chief Financial Officer
Unregistered Sales of Equity Securities
Announces Financial Results for Second Quarter 2025 and Provides Corporate Update- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 -- Positive topline results reported from VEGA-3 and LYNX
The Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
VEGA-3 Phase 3 Trial Met its Primary Endpoint
Changes in Board, Management or Compensation
Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
Q2
FY 2024
Q3
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Additional Proxy Soliciting Materials
Definitive Additional Information Statement
PRRN14A
Contested Proxy Solicitation Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Free Writing Prospectus
Definitive Revised Proxy Statement